drugset / Trial / NCT06195670
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of short course radiotherapy followed by fruquintinib combined with Sintilimab as the first-line treatment of advanced mCRC compared to bevacizumab combined with capecitabine in patients unfit for intensive therapy.
Timeline
- Start
- 2024-01
- Primary completion
- 2026-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |